Shown above CHA Biotech’s new President Lee Hyun-jung, who will head the firm’s R&D division. Photo courtesy of CHA Biotech

Pharmaceutical giant strives to strengthen R&D

South Korea’s top-tier pharmaceutical company CHA Biotech announced on Dec. 14 that it had named experienced expert Lee Hyun-jung as its new president.

Under the stewardship of CEO Oh Sang-hoon, Lee will take charge of the research and development division of the company, located south of Seoul.

Lee has longer than 20 years of experience at a variety of global healthcare corporations, including Eli Lilly, Baxalta, and Pfizer.

Over the past several years, she has spearheaded Samsung Biopharm USA.

“We hope that Lee will speed up our development of cell therapies and strengthen our footing in the international markets,” the firm said in a statement.

CHA Biotech has worked on CDMO of late.

Brief for the contract development and manufacturing organization, CDMO refers to an outfit that provides clients with comprehensive services from drug development to manufacturing.

In particular, CHA Biotech has channeled its funds and energy into research & development in the manufacturing technology related to cell and gene therapies.

The publisher studied Korean history in Seoul and management of business administration in the United Kingdom. He has 20-year experiences in the media business. Kim can be reached at or 82-2-6956-6698.